|1.||Hviid, Lars: 24 articles (01/2014 - 04/2002)|
|2.||Staalsoe, Trine: 19 articles (08/2010 - 04/2002)|
|3.||Theander, Thor G: 17 articles (02/2013 - 04/2002)|
|4.||Rogerson, Stephen J: 13 articles (09/2012 - 04/2002)|
|5.||Marsh, Kevin: 12 articles (01/2016 - 02/2002)|
|6.||Raimondo, Giovanni: 12 articles (10/2015 - 03/2006)|
|7.||Menne, Stephan: 12 articles (09/2015 - 01/2002)|
|8.||Pollicino, Teresa: 10 articles (10/2015 - 03/2006)|
|9.||Deloron, Philippe: 10 articles (01/2015 - 07/2004)|
|10.||Su, Ih-Jen: 10 articles (09/2014 - 12/2003)|
08/01/2012 - "Our results demonstrated that V. anguillarum MVAV6203 (pUTatLNG40), which harbours a low-copy plasmid-loaded antigen surface display system under the control of a constitutive promoter, presented the best protective efficacy against the infection of Vibrio anguillarum (relative per cent survival, RPS = 85%) and Edwardsiella tarda (RPS = 70%)."
12/01/1975 - "The results indicate that the surface-antigen-adsorbed vaccine induced high titres of serum antibody, and gave significant protection against challenge infection."
04/01/2006 - "Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of toxoplasma gondii induces immune response and protection against infection in mice."
03/30/1991 - "Two regimens by which vaccine was injected intradermally into children between 0 and 4 years old led to peak geometric mean (95% CI) concentrations of antibody against HBV surface antigen of 270 (202-358) and 555 (418-748) mlU/ml. The third regimen--intramuscular vaccination of children aged between 0 and 4 years--gave geometric mean peak antibody concentrations of 926 (765-1122) mlU/ml. A fourth regimen was intramuscular vaccination of children between 1 and 9 months old, which gave geometric mean antibody concentrations of 5431 (3903-75,456) mlU/ml. Despite these widely divergent responses and a 89% decay in antibody over the first 2 years, vaccination against HBV was 97% effective in preventing chronic infection. "
08/01/2008 - "Maybe the HBV strains in this study represent a natural end-stage of seemingly cleared HBV infection, in which HBV maintains a low level of possibly non-infectious replication, after sacrificing its immunologically offending surface antigen, thus avoiding final clearance by the immune system."
03/01/2005 - "Challenges that remain to be addressed if the full potential of primary cultures as a model system is to be realized include isolation, culture and characterization of stem cells, improved methodology to induce or maintain a fully differentiated, androgen-responsive phenotype, and identification of cell surface antigens or other markers with which to purify pure populations of live cancer or premalignant cells apart from non-malignant epithelial cells prior to culture."
01/01/2015 - "The anti-cancer efficacy of antibody-drug conjugates is thought to rely on their uptake by cancer cells expressing the surface antigen. "
10/20/2003 - "Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner."
06/01/2003 - "Radiolabelled MAbs against cell surface antigens have improved in vivo tumor diagnosis and treatment. "
08/15/2001 - "Using a series of human tumor cells (SNB19, SNB79, 143N2, and SHEP), we observed a distinct efficacy of human anti-FasR antibody with an apparent correlation with Fas cell surface antigen expression. "
03/01/2014 - "The aim of this study was to verify antibody levels of antibody against hepatitis B virus surface antigen (anti-HBs) in children aged 1 to 15 years who received vaccination against hepatitis B in the central province of Iran, Semnan. "
08/01/2006 - "The study describes expression and purification of recombinant hepatitis B small surface antigen (rHBsAg hereafter) in methylotrophic yeast Pichia pastoris strain GS115. "
10/01/1990 - "The results of these studies were correlated with the histopathology and immunohistochemical stains for hepatitis B core and surface antigens. "
08/01/2015 - "Serum hepatitis B virus surface antigen was present in 1,083 (68.5%) patients, and hepatitis B was found to be the only etiological factor in 938 (59.3%) of all patients. "
03/01/2015 - "To evaluate proportion and predictors of poor response in infants and appraise booster seroprotection, we surveyed 2047 infants in Shanghai and detected antibody to hepatitis B (HB) surface antigen (anti-HBs). "
08/01/2015 - "Since the discovery of circumsporozoite protein (CSP), a major sporozoite surface antigen, by Ruth Nussenzweig and Victor Nussenzweig in the early 1980s, the role of CSP in protection against malaria has been extensively investigated. "
08/01/1999 - "For 9 years we have monitored individuals living in an area of low-intensity, seasonal, and unstable malaria transmission in eastern Sudan, and we have used this database to study the acquisition, specificity, and duration of the antibody response to variant parasitized erythrocyte surface antigens. "
04/01/1997 - "In the first phase III efficacy trial of the malaria vaccine SPf66 in Africa, MOIs in SPf66- and placebo-vaccinated children were analyzed by polymerase chain reaction-restriction fragment length polymorphism of the Plasmodium falciparum merozoite surface antigen 2 (MSA2). "
02/01/1995 - "Two hundred fourteen adult individuals were selected for studies to assess their immune responses against the malaria vaccine candidate ring-infected erythrocyte surface antigen (RESA). "
07/01/1991 - "Genetic studies on a major merozoite surface antigen of the malaria parasite of rodents, Plasmodium chabaudi."
05/01/2003 - "For hepatitis surface antigen expression in eukaryotic cells, the vector pRc/CMV is superior to pSG5UTPL/Flag, and pRc/CMV-S and pRc/CMV-MS are the most efficient in the pRc/CMV clones. "
12/01/2012 - "A total of 530 children enrolled into the study, and 352 (66.4 %) of them had protective antibody to hepatitis surface antigens (anti-HBs) titer greater than 10 mIU/ml. The proportions of children with low, intermediate, and high anti-HB titers are different for those under 3 years of age. "
03/12/2007 - "Analysis comprised HIV-positive patients in the ICoNA study without acute hepatitis who had >or= 1 positive HCV antibody test and > 1 positive HBV surface antigen test. "
09/01/1996 - "During the study period of 28 days, protective antibody titers to hepatitis surface antigen (anti-HBs10 mIU ml-1) were observed in 11 of 81 subjects receiving rhGM-CSF, but in none of the controls (P = 0.035). "
10/14/2015 - "The endemicity of hepatitis surface antigen in Indonesia is intermediate to high with a geographical difference. "
|1.||Hepatitis B Surface Antigens (HBsAg)
|4.||DNA (Deoxyribonucleic Acid)
|6.||Hepatitis B e Antigens
|7.||Immunoglobulin G (IgG)
|8.||Surface Antigens (Surface Antigen)
|10.||Interferon-alpha (Interferon Alfa)
|2.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)
|5.||Highly Active Antiretroviral Therapy (HAART)